Metlife (0K0X) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0K0X Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Metlife

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0K0X Stock 12 Month Forecast

Average Price Target

$111.55

▲(15.39% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Metlife in the last 3 months. The average price target is $111.55 with a high forecast of $119.00 and a low forecast of $108.00. The average price target represents a 15.39% change from the last price of $96.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"$69","120":"$120","81.75":"$81.8","94.5":"$94.5","107.25":"$107.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$119.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.54545454545455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$108.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,81.75,94.5,107.25,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.35,95.32307692307691,97.29615384615384,99.26923076923076,101.24230769230769,103.21538461538461,105.18846153846154,107.16153846153846,109.13461538461539,111.1076923076923,113.08076923076923,115.05384615384615,117.02692307692308,{"y":119,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.35,94.74965034965034,96.1493006993007,97.54895104895104,98.9486013986014,100.34825174825174,101.7479020979021,103.14755244755244,104.5472027972028,105.94685314685314,107.3465034965035,108.74615384615385,110.1458041958042,{"y":111.54545454545455,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.35,94.47692307692307,95.60384615384615,96.73076923076923,97.8576923076923,98.98461538461538,100.11153846153846,101.23846153846154,102.36538461538461,103.49230769230769,104.61923076923077,105.74615384615385,106.87307692307692,{"y":108,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79.922,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.905,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.335,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.572,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.325,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.298,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.828,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.981,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.865,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.197,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.45,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.35,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$119.00

Average Price Target$111.55

Lowest Price Target$108.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Kligerman

TD Cowen

$110→$114

Buy

17.93%

Upside

Reiterated

10/21/26

MetLife price target raised to $114 from $110 at TD CowenMetLife price target raised to $114 from $110 at TD Cowen

Pablo Singzon

J.P. Morgan

$108→$110

Buy

13.79%

Upside

Assigned

10/15/26

MetLife price target raised to $110 from $108 at JPMorganMetLife price target raised to $110 from $108 at JPMorgan

Paul Newsome

Piper Sandler

$110

Buy

13.79%

Upside

Reiterated

10/12/26

Metlife (MET) Receives a Buy from Piper Sandler

Joshua Shanker

Bank of America Securities

$119

Buy

23.10%

Upside

Reiterated

10/12/26

Bank of America Securities Reaffirms Their Buy Rating on Metlife (MET)

Wesley Carmichael

Wells Fargo

$109→$110

Buy

13.79%

Upside

Reiterated

10/12/26

Analysts Conflicted on These Financial Names: Metlife (NYSE: MET) and Baldwin Insurance Group (NASDAQ: BWIN)

Ryan Krueger

KBW

$108

Buy

11.72%

Upside

Reiterated

10/08/26

KBW Keeps Their Buy Rating on Metlife (MET)

Yaron Kinar

Mizuho Securities

$112→$109

Buy

12.75%

Upside

Reiterated

10/07/26

MetLife price target lowered to $109 from $112 at MizuhoMetLife price target lowered to $109 from $112 at Mizuho

Alex Scott

Barclays

$97→$111

Buy

14.82%

Upside

Reiterated

10/07/26

Barclays Sticks to Its Buy Rating for Metlife (MET)

Michael Ward CFA

UBS

$105→$110

Buy

13.79%

Upside

Reiterated

10/06/26

MetLife price target raised to $110 from $105 at UBSMetLife price target raised to $110 from $105 at UBS

Bob Huang

Morgan Stanley

$111

Buy

14.82%

Upside

Assigned

10/05/26

Morgan Stanley Gives a Buy Rating to Metlife (MET)

Suneet Kamath

Jefferies

$103→$115

Buy

18.96%

Upside

Reiterated

10/01/26

Jefferies Reaffirms Their Buy Rating on Metlife (MET)

Wilma Burdis

Raymond James

―

Hold

―

Reiterated

09/29/26

Analysts Offer Insights on Financial Companies: Metlife (NYSE: MET) and Robinhood (NASDAQ: HOOD)

Thomas Gallagher

Evercore ISI

$95→$96

Hold

-0.69%

Downside

Reiterated

04/09/26

MetLife price target raised to $96 from $95 at Evercore ISIMetLife price target raised to $96 from $95 at Evercore ISI

Kevin Heal

Argus Research

$90

Buy

-6.90%

Downside

Reiterated

12/08/25

MetLife's higher investment income supporting results, says ArgusMetLife's higher investment income supporting results, says Argus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Kligerman

TD Cowen

$110→$114

Buy

17.93%

Upside

Reiterated

10/21/26

MetLife price target raised to $114 from $110 at TD CowenMetLife price target raised to $114 from $110 at TD Cowen

Pablo Singzon

J.P. Morgan

$108→$110

Buy

13.79%

Upside

Assigned

10/15/26

MetLife price target raised to $110 from $108 at JPMorganMetLife price target raised to $110 from $108 at JPMorgan

Paul Newsome

Piper Sandler

$110

Buy

13.79%

Upside

Reiterated

10/12/26

Metlife (MET) Receives a Buy from Piper Sandler

Joshua Shanker

Bank of America Securities

$119

Buy

23.10%

Upside

Reiterated

10/12/26

Bank of America Securities Reaffirms Their Buy Rating on Metlife (MET)

Wesley Carmichael

Wells Fargo

$109→$110

Buy

13.79%

Upside

Reiterated

10/12/26

Analysts Conflicted on These Financial Names: Metlife (NYSE: MET) and Baldwin Insurance Group (NASDAQ: BWIN)

Ryan Krueger

KBW

$108

Buy

11.72%

Upside

Reiterated

10/08/26

KBW Keeps Their Buy Rating on Metlife (MET)

Yaron Kinar

Mizuho Securities

$112→$109

Buy

12.75%

Upside

Reiterated

10/07/26

MetLife price target lowered to $109 from $112 at MizuhoMetLife price target lowered to $109 from $112 at Mizuho

Alex Scott

Barclays

$97→$111

Buy

14.82%

Upside

Reiterated

10/07/26

Barclays Sticks to Its Buy Rating for Metlife (MET)

Michael Ward CFA

UBS

$105→$110

Buy

13.79%

Upside

Reiterated

10/06/26

MetLife price target raised to $110 from $105 at UBSMetLife price target raised to $110 from $105 at UBS

Bob Huang

Morgan Stanley

$111

Buy

14.82%

Upside

Assigned

10/05/26

Morgan Stanley Gives a Buy Rating to Metlife (MET)

Suneet Kamath

Jefferies

$103→$115

Buy

18.96%

Upside

Reiterated

10/01/26

Jefferies Reaffirms Their Buy Rating on Metlife (MET)

Wilma Burdis

Raymond James

―

Hold

―

Reiterated

09/29/26

Analysts Offer Insights on Financial Companies: Metlife (NYSE: MET) and Robinhood (NASDAQ: HOOD)

Thomas Gallagher

Evercore ISI

$95→$96

Hold

-0.69%

Downside

Reiterated

04/09/26

MetLife price target raised to $96 from $95 at Evercore ISIMetLife price target raised to $96 from $95 at Evercore ISI

Kevin Heal

Argus Research

$90

Buy

-6.90%

Downside

Reiterated

12/08/25

MetLife's higher investment income supporting results, says ArgusMetLife's higher investment income supporting results, says Argus

Stocks with the Highest Top Analyst Consensus in the Financial Sector

BNBrookfield Corporation

SSBSouthState Corporation

RIOTRiot Platforms

AIZAssurant

BETRBetter Home & Finance

Find stocks in the Financial sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Metlife

3 Months

Ryan KruegerKBW

Success Rate

25/36 ratings generated profit

Average Return

+7.29%

Copying Ryan Krueger's trades and holding each position for 3 Months would result in 69.44% of your transactions generating a profit, with an average return of +7.29% per trade.

1 Year

Ryan KruegerKBW

Success Rate

32/36 ratings generated profit

Average Return

+18.19%

Copying Ryan Krueger's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +18.19% per trade.

2 Years

Alex ScottBarclays

Success Rate

18/18 ratings generated profit

Average Return

+29.72%

Copying Alex Scott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0K0X Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0K0X has received 22 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0K0X average Analyst price target in the past 3 months is 111.55.

Each month's total comprises the sum of three months' worth of ratings.

0K0X Financial Forecast

0K0X Earnings Forecast

Next quarter’s earnings estimate for 0K0X is $2.77 with a range of $2.62 to $2.91. The previous quarter’s EPS was $2.43. 0K0X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 81.82% of the time in the same period. In the last calendar year 0K0X has Performed in-line its overall industry.

0K0X Sales Forecast

Next quarter’s sales forecast for 0K0X is $19.86B with a range of $19.20B to $20.24B. The previous quarter’s sales results were $19.31B. 0K0X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 93.33% of the time in the same period. In the last calendar year 0K0X has Performed in-line its overall industry.

0K0X Stock Forecast FAQ

What is GB:0K0X’s average 12-month price target, according to analysts?

Based on analyst ratings, Metlife’s 12-month average price target is 111.55.

What is GB:0K0X’s upside potential, based on the analysts’ average price target?

Metlife has 15.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Metlife a Buy, Sell or Hold?

Metlife has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Metlife’s share price target?

The average share price target for Metlife is 111.55. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $119.00 ,and the lowest forecast is $108.00. The average share price target represents 15.39% Increase from the current price of $96.67.

What do analysts say about Metlife?

Metlife’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Metlife?

To buy shares of GB:0K0X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Metlife (0K0X) Share Forecast & Price Target

0K0X Analyst Ratings

0K0X Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Metlife

0K0X Analyst Recommendation Trends

0K0X Financial Forecast

0K0X Earnings Forecast

0K0X Sales Forecast

0K0X Stock Forecast FAQ

Detailed List of Analyst Forecasts